# A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

> **NCT06018337** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **DualityBio Inc.** · enrollment: 541 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** DB-1303/BNT323
- **DRUG:** Capecitabine
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT06018337
- **Lead sponsor:** DualityBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-18
- **Primary completion:** 2026-05
- **Final completion:** 2028-07
- **Target enrollment:** 541 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06018337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06018337, "A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06018337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*